Park G Kate, Lee Jeong Heon, Soriano Eduardo, Choi Myunghwan, Bao Kai, Katagiri Wataru, Kim Do-Yeon, Paik Ji-Hye, Yun Seok-Hyun, Frangioni John V, Clancy Thomas E, Kashiwagi Satoshi, Henary Maged, Choi Hak Soo
Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Department of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, 100 Piedmont Ave SE, Atlanta, Georgia 30303, USA.
iScience. 2020 Apr 24;23(4):101006. doi: 10.1016/j.isci.2020.101006. Epub 2020 Mar 25.
Design of tissue-specific contrast agents to delineate tumors from background tissues is a major unmet clinical need for ultimate surgical interventions. Bioconjugation of fluorophore(s) to a ligand has been mainly used to target overexpressed receptors on tumors. However, the size of the final targeted ligand can be large, >20 kDa, and cannot readily cross the microvasculature to meet the specific tissue, resulting in low targetability with a high background. Here, we report a small and hydrophilic phenoxazine with high targetability and retention to pancreatic neuroendocrine tumor. This bioengineered fluorophore permits sensitive detection of ultrasmall (<0.5 mm) ectopic tumors within a few seconds after a single bolus injection, highlighting every tumor in the pancreas from the surrounding healthy tissues with reasonable half-life. The knowledge-based approach and validation used to develop structure-inherent tumor-targeted fluorophores have a tremendous potential to improve treatment outcome by providing definite tumor margins for image-guided surgery.
设计组织特异性造影剂以区分肿瘤与背景组织是最终手术干预尚未满足的主要临床需求。将荧光团与配体进行生物共轭主要用于靶向肿瘤上过度表达的受体。然而,最终靶向配体的尺寸可能很大,大于20 kDa,并且不能轻易穿过微血管到达特定组织,导致靶向性低且背景高。在此,我们报告了一种对胰腺神经内分泌肿瘤具有高靶向性和滞留性的小尺寸亲水性吩恶嗪。这种生物工程荧光团允许在单次推注注射后几秒钟内灵敏地检测超小(<0.5 mm)异位肿瘤,以合理的半衰期将胰腺中的每个肿瘤与周围健康组织区分开来。用于开发具有结构固有肿瘤靶向性荧光团的基于知识的方法和验证,通过为图像引导手术提供明确的肿瘤边界,具有改善治疗结果的巨大潜力。